Skip to content
Archives:

Pregnant women have frequently been excluded from or de-prioritized in clinical research initiatives due to a multitude of factors, such as the complex physiology of pregnant women, the risk studies may pose to the fetus, and the classification of pregnant women as a vulnerable population, among others. This neglect has left pregnant women and their providers to make decisions without adequate information or guidance regarding the safety and efficacy of necessary treatments.

This was a two part webinar series; Part I was held on Wednesday, February 14th, and was intended to broaden and build the capacity of civil society and other partners interested in issues related to pregnant and lactating women and research. Part II was held on Wednesday, March 14th, and focused on more disease-specific efforts to include pregnant women in tuberculosis (TB) and HIV research. Below you’ll find all the materials that were presented and shared during both parts of the webinar.

PART I:

   

Moderator: Kathryn Schubert, Chief Advocacy Officer, The Society for Maternal-Fetal Medicine (SMFM)

Panelists:

–For additional information about the Task Force on Research Specific to Pregnant and Lactating Women (PRGLAC): https://www.nichd.nih.gov/About/Advisory/PRGLAC

–For additional information about the Coalition for Advancing Maternal Therapeutics (CAMT): https://www.smfm.org/advocacy/camt

 

Part II:

Moderator: Dr. Jyoti Mathad, Assistant Professor of Medicine and Obstetrics and Gynecology in the Center for Global Health at Weill Cornell Medical College

If you have any questions, please direct them to Lindsay McKenna.

Back To Top